United Cannabis Corporation was founded to advance the use of CBD’s, or cannabidiols, in medicine through research, product development and education. The Company is dedicated to improving the lives of patients through the creation of products using only the highest quality genetics, purest extractions and most effective protocols possible. The Company’s A.C.T. Now Program and patent pending Prana Bio Nutrient Medicinals provide a comprehensive solution, designed to enable physicians and patients to design, implement and monitor effective therapy protocols.
To provide patented and cutting-edge pharmaceutical CBD formulations, United Cannabis (UCANN) has entered into exclusive and long-term contracts with Dr. Brent Reynolds, currently a professor in the Department of Neurosurgery at the University of Florida, and Dr. Dennis Steindler Senior Scientist, director of the neuroscience and aging lab at Tufts University, as chief medical advisors to run and manage discovery, research and development for UCANN.
Its primary focus is to explore the medical applications of CBD’s. UCANN entered into a consulting contract with doctors Brent A. Reynolds Ph.D. and Dennis A. Steindler Ph.D., pursuant to which they will act as UCANN’s research and development team to establish evidence of CBD-based medical efficacy and creation of Intellectual Property (IP) on medically efficient CBD-based products. Both are employed by division-one universities and run their respective departments. UCANN will own all the inventions or discoveries coming from the contractual relationship.
Drs. Reynolds and Steindler have a record of patent protection and product development. Jointly, they have published over 200 peer-reviewed manuscripts in journals such as Nature, Science, Nature Reviews Cancer, Cell and Cancer Research. The Doctors hold 19 granted U.S. patents, have founded several biotechnology companies and have developed products that are currently in the marketplace. Their experience in basic discovery and translating this into protected technology will allow UCANN to leverage its existing technology platform with the objective of producing unique and effective cannabinoid medications.
As a result of the doctors’ work so far, 14 unique provisional patents related to the unique combinations of pharmaceutically active CBD’s used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.
The doctors continue to work with United Cannabis to further development of CBD’s designed to combat a wide range of ailments that plague humans and animals.